Sequence variation and linkage disequilibrium in the GABA transporter-1 gene (SLC6A1) in five populations: implications for pharmacogenetic research
- Rungnapa Hirunsatit1, 2, 3,
- Risto Ilomäki4,
- Robert Malison1,
- Pirkko Räsänen4,
- Essi Ilomäki4,
- Henry R Kranzler5,
- Thomas Kosten1, 2,
- Atapol Sughondhabirom6,
- Nuntika Thavichachart6,
- Sookjaroen Tangwongchai6,
- Jennifer Listman7,
- Apiwat Mutirangura8,
- Joel Gelernter1, 2 and
- Jaakko Lappalainen1, 2Email author
© Hirunsatit et al; licensee BioMed Central Ltd. 2007
Received: 17 January 2007
Accepted: 17 October 2007
Published: 17 October 2007
GABA transporter-1 (GAT-1; genetic locus SLC6A1) is emerging as a novel target for treatment of neuropsychiatric disorders. To understand how population differences might influence strategies for pharmacogenetic studies, we identified patterns of genetic variation and linkage disequilibrium (LD) in SLC6A1 in five populations representing three continental groups.
We resequenced 12.4 kb of SLC6A1, including the promoters, exons and flanking intronic regions in African-American, Thai, Hmong, Finnish, and European-American subjects (total n = 40). LD in SLC6A1 was examined by genotyping 16 SNPs in larger samples. Sixty-three variants were identified through resequencing. Common population-specific variants were found in African-Americans, including a novel 21-bp promoter region variable number tandem repeat (VNTR), but no such variants were found in any of the other populations studied. Low levels of LD and the absence of major LD blocks were characteristic of all five populations. African-Americans had the highest genetic diversity. European-Americans and Finns did not differ in genetic diversity or LD patterns. Although the Hmong had the highest level of LD, our results suggest that a strategy based on the use of tag SNPs would not translate to a major improvement in genotyping efficiency.
Owing to the low level of LD and presence of recombination hotspots, SLC6A1 may be an example of a problematic gene for association and haplotype tagging-based genetic studies. The 21-bp promoter region VNTR polymorphism is a putatively functional candidate allele for studies focusing on variation in GAT-1 function in the African-American population.
γ-aminobutyric acid (GABA) is the most ubiquitous inhibitory neurotransmitter in brain. Abnormal function of the GABA system has been implicated in almost every common neurological and psychiatric disorder. Augmentation of brain GABA function is the presumed therapeutic mechanism of several classes of medications, including the benzodiazepines, gabapentin, and pregabalin, which are used in treatment of many psychiatric and neurological disorders, addictions, and pain [1, 2]. Identifying genetic factors responsible for variation in clinical response holds promise as a way to improve the clinical application of these medications; it may be possible to identify those who are most likely to respond to treatment and those who are at risk to develop adverse effects. For these kinds of studies, it will be important to identify polymorphisms in genes encoding the components of the brain GABA system. Although the HapMap project  will identify the major basic blocks of linkage disequilibrium in these genes, detailed patterns of genetic variation, including the discovery of novel functional variants, can only be accomplished through resequencing.
A novel class of medications was recently developed that act by blockade of GABA transporters (GAT), thereby inhibiting GABA uptake. Four main subtypes of GABA transporters, the GAT-1, GAT-2, GAT-3 and Betaine/GABA transporter-1 (BGT-1), have been identified through molecular cloning. The first medication in the GABA reuptake inhibitor class to become available for clinical use was tiagabine [(-)-(R)-1-(4,4-Bis(3-methyl-2-thienyl)3-butenyl) nipecotic acid hydrochloride], which selectively blocks GAT-1 sites . Tiagabine was developed for treatment of seizure disorders but is being used by many psychiatrists to treat a variety of conditions in which augmentation of brain GABA function is thought to be desirable to alleviate clinical symptoms. Preliminary studies suggest that tiagabine is effective in treatment of anxiety , sleep disorders , depression  and addictions [2, 8, 9]. Animal studies suggest that most of the tiagabine's common adverse effects, such as muscle twitching and sedation, arise from specific inhibition of GAT-1 . Tiagabine has a rare, but serious adverse effect – non-convulsive status epilepticus – which has raised concerns about its off-label use in treatment of psychiatric disorders . Pharmacogenetic study could plausibly help to identify those subjects who are at greatest risk for developing side-effects to tiagabine and other medications that inhibit GAT-1.
The SLC6A1 gene, which encodes the GAT-1 protein, is an obvious candidate for pharmacogenetic studies of tiagabine and other GAT-1 inhibitors . In anticipation of larger pharmacogenetic studies, we aimed to identify novel genetic variation and examine linkage disequilibrium in the SLC6A1 gene in five populations representing three major continental groups [European (EA and Finnish), African (AA) and Asian (Thai and Hmong)]. Populations considered isolated, Finnish and Hmong, and two mixed populations, EA and AA, were examined, to understand how population differences should influence planning for pharmacogenetic studies. By comparing isolated and mixed populations, we hoped to shed further light on the purported benefits of isolated populations in mapping complex genetic traits [13, 14]. Furthermore, our goal was to identify a set of haplotype tagging markers for studies focusing on response to GAT-1 inhibition. However, very low levels of LD was discovered in SLC6A1 gene suggesting that traditional haplotype-based approaches of examining this gene in pharmacogenetic studies would be of limited utility.
Algorithmic promoter prediction
The sequence for SLC6A1, located in contig NT_022517, which contains the sequence for human chromosome 3, was used as a reference. ElDorado software  located two putative SLC6A1 promoter regions in the contig at positions 10973950–10974553 and 10998399–10998999 (+ strand). The first region is located in an area surrounding the boundary between the 5' region and exon 1 of SLC6A1 and isestimated to be 604 bp long. Hereafter, we refer to this region as the upper promoter region. The second putative promoter region of 601 bp was located in the area flanking the boundary between intron 2 and exon 3. This region extends 70 bp across the SLC6A1 start codon in the 3' direction in exon 3. We refer to this region as the lower promoter region.
Nucleotide diversity in SLC6A1 in five populations
The SLC6A1 promoter regions, 16 exons, and the flanking intronic regions were amplified and resequenced in 7–9 samples from each of the five populations. A total of 61 SNPs were found in the sequencing screening sample, including 5 SNPs in the promoter regions, 3 synonymous coding sequence SNPs, and 53 non-coding region SNPs. No non-synonymous SNPs were found. The identified SLC6A1 variants, including frequency in the screening sample, location, and flanking sequence are provided in the additional data file 1.
Indices of SLC6A1 nucleotide diversity in five populations.
Number of polymorphic sites
Nucleotide diversity per bp (π) (10-4)
Watterson's estimator of theta (θ) (10-4)
Mean number of heterozygous SNPs per person
Novel length polymorphisms in the promoter region
A novel two-base-pair deletion (GG/-GG) at positions (-24780 to -24781) was present in all 5 populations studied. This polymorphism is located only 8 bp 3' to the last base pair of the short/long polymorphism. The -GG allele occurs only in the context of the short allele.
The SLC6A1 short/long and GG/-GG polymorphisms were genotyped in 46 EA, 60 AA, 59 Thai, 47 Finnish and 48 Hmong individuals. The allele frequency of the long allele was 0.39 in the AA sample but it was not found in other populations. The GG/-GG polymorphism occurred in all 5 populations. The -GG allele frequency was 0.30 in EA, 0.23 in AA, 0.33 in Finnish, 0.22 in Thai and 0.16 in Hmong.
Linkage disequilibrium in the SLC6A1 gene
Haplotype diversity in SLC6A1
A summary pairwise percentage score representing the degree to which the four most common haplotypes were disjoint between the five populations.
Recombination hotspots in SLC6A1
We considered recombination hotspots as an explanation for low level LD in SLC6A1. Recombination rates were calculated for the genotype data using the -MR and -X10 options of the PHASE program [20, 21] and genotype data for all 16 SLC6A1 SNPs. Average recombination rates in the five populations are shown in Figure 2. These data show two areas in SLC6A1 with elevated recombination rates. The first area is demarcated by markers -29477 (Marker 1) and -13071 (Marker 4) and the second one by markers 7772 (Marker 9) and 20172 (Marker 15), hereafter referred to as the upper and lower hotspots, respectively. There were population differences in the amplitude of the hotspots (Figure 2). In the upper hotspot, which is located in the areas of intron 1 and exon 1, an increase in the recombination rate was observed in all five populations. The Hmong and AA populations showed lower rate and width of the lower hotspot, located in the area between exon 8 and 16, than did the EAs, Finns or Thai (Figure 2). To further elucidate these findings, we analyzed SLC6A1 genotypes available through HapMap using PHASE, as described above. Genotyping data for the combined group of Japanese and Han Chinese, Yoruba, and Western Europeans were analyzed and compared to our results. We compared genotype data from our 16 SNPs and genotype data from 27–31 SNPs in HapMap. Two sets of SNPs, our and the HapMap SNPs, are not exactly the same but they are all located within the SLC6A1 gene (one dot on X-axis in Figure 2 represents one SNP). It appears that genotype data from the two samples (the present study and HapMap) are consistent, both showing evidence for two areas of increase in recombination rate within SLC6A1. These results support our findings (Figure 2) regarding two recombination hotspots in SLC6A1.
The goal of the present study was to comprehensively analyze sequence variation and linkage disequilibrium in the SLC6A1 gene in anticipation of larger pharmacogenetic studies of tiagabine and other GAT-1 inhibitors. Resequencing 12.4 kb of the SLC6A1 gene, including all 16 exons and the two putative promoter regions, revealed numerous novel genetic variants. Perhaps the most interesting polymorphism identified was a 21 bp VNTR polymorphism located in the upper promoter sequence of the SLC6A1 gene (Figure 1). We have termed the alleles as the "SLC6A1 short," which has one copy of the allele and "SLC6A1 long," in which the allele is duplicated (Figure 1). Interestingly, the long allele was common in AAs (39%), while in the other populations, it was absent. A likely explanation for the lack of this allele in non-African populations is genetic drift. However, other explanations, such as natural selections, are also possible. Functional studies focusing on understanding whether the short and long allele lead to differential expression of the GAT-1 protein are clearly warranted; these studies may also help in elucidating whether the allele frequency discrepancy between African-Americans and other populations is due to genetic drift or selection. Previously, a comparable promoter region VNTR polymorphism was described in the serotonin transporter gene, which is known to influence the expression of the gene . Several studies have shown that this polymorphism partially accounts for differences in the therapeutic response to serotonin selective reuptake inhibitors (SSRIs) [23–26], susceptibility to depression [27, 28] and alcohol dependence . The SLC6A1 short/long is a candidate polymorphism for moderating the response to tiagabine and susceptibility to neuropsychiatric disorders in which GABA dysfunction may play a role, albeit only in AA populations (and any other populations where this variant is present).
Genetic diversity in SLC6A1 revealed through SLC6A1 resequencing showed interesting results. Although a limited number of chromosomes was examined, certain trends were found. First, no non-synonymous SNPs were discovered in the 80 chromosomes sequenced, suggesting that the coding sequence of SLC6A1 has been conserved against common amino-acid altering substitutions through active background selection. Consistent with these results, the nucleotide diversity was much lower in the SLC6A1 exons compared to the intronic regions examined [30–32]. Comparison of the sequence data between populations revealed higher nucleotide diversity in AAs than in other populations (Table 1). In accordance with these data, the only population in which we found common population specific SNPs, were AAs. In exons, however, nucleotide diversity was no higher in the AA population than in the other populations. In other populations, the SNPs observed in only one population were rarer. Although Finns and Hmong are considered to be isolated populations, nucleotide diversity in these two populations was not different from that observed in EAs or Thais. Overall, no major differences in nucleotide diversity were observed among the Hmong, Thai, EA, and Finnish populations. Together, these findings most likely reflect the older age of the African population relative to the other populations, which had allowed more intronic variation to accumulate in this population, founder effects in non-African populations, and selection pressure conserving the SLC6A1 exonic sequence. The extent of conservation of GAT-1 amino acid sequence suggests an important role of this protein in normal brain function. The Hmong had a significantly lower number of heterozygous SNPs in comparison to the other populations. One explanation for this finding is that the Hmong subjects may have been distantly related. We postulate that differences in the degree and age of population bottlenecks between the Hmong and the other populations are less likely explanations for the lower heterozygosity observed in the Hmong; we feel that this explanation is less likely because all non-African populations had a low observed frequency of population-specific SNPs and because Hmong nucleotide diversity was not significantly lower than that of the other non-African populations . A caveat of this study is that the sample size per ethnicity was small. Consequently, rare non-synonymous SNPs, specific to a population, would have not been identified. It may be useful to resequence larger samples to identify these kinds of variations, at least in the primary target populations of clinical trials. Laboratory methods established for the present study should facilitate such analyses. Another limitation of the study is that the resequencing effort focused on exons. If deep intronic variation in SLC6A1 contributes to functional variation at the protein level, those variants would have been missed in the present study. A low level of LD in SLC6A1 was observed in all five populations (Figure 2). Consistent with these results, in the EA, Thai, Hmong, and Finnish populations, only two or three haplotype tagging SNPs in the areas of preserved LD were identified. In the AAs, no haplotype tagging SNPs were found in the 16 SNPs genotyped. These results suggest that very dense SNP panels would be required to capture common variation in this gene. Using r2/distance as the index, a longer LD span was observed in the Hmong population than in the other populations (Figure 3). However, higher LD probably would not translate to significant practical improvement in genotyping efficiency overall, because there were no major differences in the number of haplotype blocks in Hmong than in the Finnish, Thai and EA populations. Considering the low level of LD, SLC6A1 may pose special challenges for association studies both in isolated and mixed populations. The common SLC6A1 3-SNP haplotypes were largely the same in the five populations (Table 2), but were not completely overlapping. These results suggest a certain degree of, but not absolute, portability of SNP genotyping sets between the populations. It would interesting to study larger EA, AA, Hmong, Thai and Finnish population samples to further refine the structure and frequencies of the common overlapping and population-specific haplotypes . In addition, it will be interesting to study whether haplotype and SNP profile characteristics, such as absence of common non-synonymous substitutions extends to patient populations suffering from various neuropsychiatric disorders, which were not studied here. The present study primarily focused on non-clinical samples and therefore no data were available to assesses whether disease associated variants are present in human populations.
Intrigued by these findings, we examined whether recombination hotspots could explain low levels of LD in SLC6A1. Two hotspots were identified using PHASE; the first is located in the areas of exon 1 and intron 1. The second hotspot is located in the area demarcated by exons 8 and 16. As expected, within the hotspots, D' fell off rapidly. For example, in the Finns, in the area of the distal hotspot, D' was only 0.184 between markers 12 and 13, which are spaced 107 bp apart and D' was 0.044 between 13 and 14, which are spaced 489 bp apart. Areas of high recombination, such as seen in SLC6A1, potentially limit large-scale association studies, as it would be exceptionally difficult to find risk alleles relying on linkage disequilibrium if the alleles were located inside a recombination hotspot.
SLC6A1 is a complicated target for pharmacogenetic studies because low levels of LD and recombination hotspots would make it difficult to establish an association between genetic markers and response to GAT-1 modulation. Furthermore, our study suggests that focusing on isolated populations, such as Finns or Hmong, would not provide major benefits to genotyping efficacy of SLC6A1. An interesting 21-bp VNTR polymorphisms (SLC6A1 short and SLC6A1 long) was discovered in the promoter sequence of the SLC6A1 gene, which is common in African-Americans. This new polymorphism is a novel candidate for studies focusing on genetically influenced differences in GAT-1 expression, and hence, response to medications that inhibit GAT-1 function.
For re-sequencing of the SLC6A1 gene, 40 genomic DNA samples were collected from unrelated individuals representing 5 different populations: EA (n = 7), AA (n = 9), Finnish (n = 8), Thai (n = 8), and Hmong (n = 8). The Finnish subjects were unrelated parents of adolescent subjects who were participating in an epidemiological study focusing on the identification of risk factors for early-onset mental illness and substance dependence in Finland . The Thai and Hmong populations were collected in Thailand as part of an ongoing genetic association and population genetic study. The Thais selected for resequencing had grandparents and parents of Thai ancestry (Thai-Thai) or had mixed Thai and Chinese ancestry (Thai-Chinese), by subject report. These samples were obtained from a blood drive in Bangkok, Thailand. The Hmong subjects were recruited in a Hmong village in the northern part of Thailand. The AA and EA samples have been described earlier elsewhere . Both EA and AA samples were self-identified and confirmed as such by Bayesian marker clustering . All subjects provided informed consent as approved by the appropriate institutional review boards. In addition, 46 EA, 60 AA, 59 Thai, 47 Finnish and 48 Hmong individuals were genotyped for 16 SLC6A1 SNPs to examine linkage disequilibrium (LD) in this gene. The Thai subjects selected for examination of linkage disequilibrium were Thai-Thai. Recruitment and population characteristics of subjects selected for SLC6A1 genotyping were identical of subjects selected for resequencing [35, 36]. The participants were recruited from non-clinical populations. No detailed medical information was available for most of the participants. Therefore biases deriving from undetected medical conditions of the control sample could not be controlled. All studies described in this article were conducted according to the Declaration of Helsinki. The studies were approved by the institutional review boards of Yale University School of Medicine, West Haven VA Hospital, Northern- Ostrobothnia Hospital District (University of Oulu, Finland) and Chulalongkorn University (Bangkok, Thailand). All subjects signed a written informed consent for participation in this study.
The ElDorado program of the Genomatix software package was used to predict the location of the SLC6A1 promoter region . The sequence of the SLC6A1 gene submitted to the promoter region analysis was obtained from the National Center for Biotechnology Information (NCBI) .
Amplification and sequencing
For sequencing of SLC6A1, the upper and lower promoter regions, all 16 SLC6A1 exons (total of 4.4 kb) and 7.3 kb of flanking intronic regions were amplified. About 70 bp of the predicted 601 bp of the lower promoter region were not included in the sequence analysis. Approximately 12.4 kb of the SLC6A1 gene was amplified, corresponding to about 25% of the total length of the gene. All primers were designed with the PRIMER3 software . Primers were obtained from Invitrogen (Carlsbad, CA). PCR amplification was optimized before sequencing by testing different cycling conditions. Betaine (Sigma Aldrich, St. Louis, MO) at 0.5–1 M final concentrations was added to the reactions, as needed, to enhance specificity and yield of PCR amplification. PCR reactions were carried out in 15 μl volumes containing 20 ng genomic DNA, 200 μM of dNTPs mix (Stratagene, La Jolla, CA), 1 μM of mixed primers forward and reverse, 1X PC2 buffer, 0.75 U of KlenTaq1™ (Ab Peptides, St Louis, MO) and 0.5–1 M betaine when needed. Thermocycling conditions consisted of an initial denaturation step at 95°C for 5 min, 30 cycles of denaturation step at 95°C for 30 sec, an annealing step at 60–65°C 30 sec, and an extension step at 72°C. The duration of the extension step varied from 30 sec to 2 min depending on the length of the amplicon. After optimization, genomic DNA samples from each population were PCR amplified followed by purification with MinElute PCR purification columns (Qiagen, Valencia, CA) or the reaction mixtures were treated with ExoSAP-IT (USB, Cleveland, OH) to remove excess nucleotides and primers. Purified PCR samples were sequenced in the forward and reverse directions at Yale University W.M Keck Foundation Biotechnology Resource Laboratory. Sequencing reactions were conducted using the BigDye Terminator v3.1 cycle sequencing kit and an ABI 9800 Thermocycler (Applied Biosystem, Foster city, CA). Sequencing reactions were analyzed on an ABI 3730 xl DNA Analyzer (Applied Biosystems, Foster city, CA). Owing to technical problems, approximately 300 bp in exon 7 and intron 8 (2.4% from total 12.4 kb sequenced region) is missing in the sequencing data in Thai and Hmong populations (see additional data file 1).
Owing to the repeat elements contained in the identified upper promoter sequence and homologous sequences within the SLC6A1, the upper promoter region and parts of exon 1 were amplified using nested PCR. In addition, for amplification of a 180 bp fragment located in the junction of the 5' upstream region and exon 1, a region which is very high in CG content, 7-deaza-dGTP (New England BioLabs, Beverly, MA) was added to the reactions.
Genotyping and linkage disequilibrium study
A total of 16 SNPs were chosen for genotyping in population samples to examine haplotype structure of the SLC6A1 gene. Nine SNPs chosen for genotyping were identified through resequencing: -24321A/C, -1529A/G, 949A/G, 3164C/T, 14351A/G, 16009A/G, 16116C/T, 20172C/T and 20622A/G. The remaining seven SNPs, -29477C/T, -17590C/T, -13071A/G, -9765C/T, 7772A/G, 13269C/T, and 16605C/T, were chosen from the NCBI dbSNP  collection. Of the 16 SNPs studied, 14 were available through Applied-Biosystem's Assay-On-Demand service (Applied Biosystems, Foster city, CA). One assay was custom designed and obtained through the ABI's Assay-by-Design service (Applied Biosystems, Foster city, CA). PCR amplification of the 5' nuclease assays were conducted using 1 ng of DNA, 1X TaqMan universal PCR master mix (Applied Biosystems, Foster city, CA), 0.5X SNP genotyping assay mix [Applied Biosystems, Foster city, CA]. PCR conditions were as follows: denaturation step of 95°C for 10 min, followed by 50 cycles of 95°C for 15 sec and 60°C for 1 min. Amplification was performed on PTC-200 cyclers (MJ Research, Hercules, CA) and data were analyzed using the ABI Prism 7900HT Sequence Detector System and software version 2.1 (Applied Biosystem, Foster city, CA). All samples were run in duplicate for quality control purposes. Based on comparison of the duplicate runs, we estimated the genotyping error rate to be less than 0.05%. The -24321A/C SNP was genotyped using 7-deaza-dGTP sequencing because its location inside a GC-rich region made it very difficult to design a 5' nuclease assay for this SNP.
Genotyping of the length polymorphisms
Amplification of the region containing the 21 bp short/long VNTR and 2 bp GG/-GG insertion/deletion polymorphisms was accomplished using primers 5'AAGGAGAGAGATTGGAGCG 3' and 5'CTTCTTTCCTCTCGCATTC 3' (Invitrogen, Carlsbad, CA). PCR reactions were conducted in 15 μl volumes containing 20 ng genomic DNA, 200 μM of dNTPs mix (Stratagene, La Jolla, CA), 1 μM of mixed reverse and forward primers, 1X PC2 buffer, 0.75 U of KlenTaq1™ (Ab Peptides, St Louis, MO) and 1 M Betaine. The thermocycling conditions consisted of an initial step at 95°C for 5 min, 30 cycles of denaturation at 95°C for 30 sec, annealing 60°C 30 sec, and extension 72°C 30 sec. The lengths of the PCR products corresponding to the long and short alleles are 166 bp and 145 bp. The long and short alleles were separated using 3% metaphore agarose and gel electrophoresis (ISC BioExpress, Kaysville, UT). The GG/-GG insertion/deletion polymorphism was genotyped using direct sequencing of the PCR product as described in above.
Indices of sequence variation in SLC6A1 were calculated using a web application SLIDER . These indices included the number of polymorphic sites, nucleotide diversity per base pair (π) and the Watterson's estimator of theta (θ). Nucleotide diversity per base pair (π) describes the mean number of differences per site between two sequences chosen at random from a sample of sequences. The Watterson's estimator of theta (θ) is the observed number of SNPs adjusted for the sample size and new mutation rate expected to occur in each generation . In addition, for each subject we calculated the number of heterozygous SNPs observed in the sequence data. The number of heterozygous SNPs was compared between populations using ANOVA followed by post hoc Fisher's Least Significant Difference-test.
PHASE software, which implements a Bayesian algorithm for haplotype reconstruction, was used to estimate haplotype frequencies [18, 19]. PHASE's options -X10 and -MR were used to estimate recombination rates across SLC6A1 [20, 21]. The value on the Y-axis of Figure 2 shows changes in recombination parameter (ρ) per base pair of SLC6A1 exceeding the background recombination rate [20, 21]. The average recombination rate was estimated based on 1,000 burn-ins and 1,000 iterations. Recombination frequencies at SLC6A1 were compared visually between our and HapMap data. No statistical analyses were performed. To evaluate haplotype diversity among populations, we studied how often the most common haplotypes were shared or disjoint. The haplotypes were identified using a sliding window analysis across every three consecutive SLC6A1 SNPs. The four most common three-SNP haplotypes in each window and in each population were identified. The rationale for choosing the four most common haplotypes for this analysis was that visual inspection of the haplotype frequencies told us that in each window and in each population virtually all variation in haplotype diversity was captured by the four most common haplotypes. The average percent of all haplotypes captured by the top four haplotypes was 96%. We then calculated how many times each of the common three-SNP haplotype was disjoint between the populations. A summary pairwise score derived for the populations is presented in Table 2.
LD patterns in SLC6A1 were visualized using HAPLOVIEW version 3.2 We used the Tagger algorithm, implemented in HAPLOVIEW, to search for haplotype tagging SNPs in SLC6A1.  We used the default Tagger thresholds r2 > 0.8 and LOD score > 3. POWERMARKER  was used to calculate allele frequencies and examination of Hardy-Weinberg equilibrium (HWE). To illustrate differences in the span of LD in the five populations, r2 was plotted against physical distance. To do this, r2 was calculated for all SNP pairs. Because these values were not normally distributed, median values are presented. Physical distance (bp) was divided into distance bins to illustrate population differences in LD span across a range of physical distances. Median r2 in distance bins (0.1–10 kb, 10.01–20 kb etc) in different populations is presented in Figure 3. No statistical analyses were performed on these data. Software CENSOR was used to search for repeat elements within the recombination hotspots [43, 44].
- SLC6A1 :
solute carrier family 6 (neurotransmitter transporter GABA), member 1
single nucleotide polymorphisms
analysis of variance
run 10 times
Watterson's estimator of zeta
log of the likelihood odds ratio
Supported by the National Institutes of Health (K08 AA13732, R01 AA11330, P50 AA12870, M01 RR06192, K05 AA14906, K24 AA13736, R01 AA011321-04, P50-AA03510, K24 MH64122, P50 DA018197), the Alcoholic Beverage Medical Research Foundation (ABMRF), the US Department of Veterans Affairs [VA Alcohol Research Center, VA Mental Illness Research, Education and Clinical Center (VA MIRECC), and VA Veterans Research Enhancement Award Program (VA REAP)] and Thailand Research Fund. Technical help of Greg Dalton-Key, Ann Marie Lacobelle Wantroba and Katarzyna Kanarek is also greatly appreciated. Special thanks to Chupong Ittiwut for help with the illustrations.
- LaRoche SM, Helmers SL: The new antiepileptic drugs: clinical applications. Jama. 2004, 291 (5): 615-620. 10.1001/jama.291.5.615.View ArticlePubMedGoogle Scholar
- Sofuoglu M, Kosten TR: Novel approaches to the treatment of cocaine addiction. CNS Drugs. 2005, 19 (1): 13-25. 10.2165/00023210-200519010-00002.View ArticlePubMedGoogle Scholar
- Thorisson GA, Smith AV, Krishnan L, Stein LD: The International HapMap Project Web site. Genome Res. 2005, 15 (11): 1592-1593. 10.1101/gr.4413105.PubMed CentralView ArticlePubMedGoogle Scholar
- Fink-Jensen A, Suzdak PD, Swedberg MD, Judge ME, Hansen L, Nielsen PG: The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol. 1992, 220 (2-3): 197-201. 10.1016/0014-2999(92)90748-S.View ArticlePubMedGoogle Scholar
- Rosenthal M: Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry. 2003, 64 (10): 1245-1249.View ArticlePubMedGoogle Scholar
- Mathias S, Wetter TC, Steiger A, Lancel M: The GABA uptake inhibitor tiagabine promotes slow wave sleep in normal elderly subjects. Neurobiol Aging. 2001, 22 (2): 247-253. 10.1016/S0197-4580(00)00232-3.View ArticlePubMedGoogle Scholar
- Carpenter LL, Schecter JM, Tyrka AR, Mello AF, Mello MF, Haggarty R, Price LH: Open-label tiagabine monotherapy for major depressive disorder with anxiety. J Clin Psychiatry. 2006, 67 (1): 66-71.View ArticlePubMedGoogle Scholar
- Gonzalez G, Sevarino K, Sofuoglu M, Poling J, Oliveto A, Gonsai K, George TP, Kosten TR: Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction. 2003, 98 (11): 1625-1632. 10.1046/j.1360-0443.2003.00544.x.View ArticlePubMedGoogle Scholar
- Sofuoglu M, Mouratidis M, Yoo S, Culligan K, Kosten T: Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl). 2005, 181 (3): 504-510. 10.1007/s00213-005-0010-y.View ArticleGoogle Scholar
- Chiu CS, Brickley S, Jensen K, Southwell A, McKinney S, Cull-Candy S, Mody I, Lester HA: GABA transporter deficiency causes tremor, ataxia, nervousness, and increased GABA-induced tonic conductance in cerebellum. J Neurosci. 2005, 25 (12): 3234-3245. 10.1523/JNEUROSCI.3364-04.2005.View ArticlePubMedGoogle Scholar
- Flowers CM, Racoosin JA, Kortepeter C: Seizure activity and off-label use of tiagabine. N Engl J Med. 2006, 354 (7): 773-774. 10.1056/NEJMc055301.View ArticlePubMedGoogle Scholar
- Kurland L, Lind L, Melhus H: Using genotyping to predict responses to anti-hypertensive treatment. Trends Pharmacol Sci. 2005, 26 (9): 443-447.PubMedGoogle Scholar
- Eaves IA, Merriman TR, Barber RA, Nutland S, Tuomilehto-Wolf E, Tuomilehto J, Cucca F, Todd JA: The genetically isolated populations of Finland and sardinia may not be a panacea for linkage disequilibrium mapping of common disease genes. Nat Genet. 2000, 25 (3): 320-323. 10.1038/77091.View ArticlePubMedGoogle Scholar
- Shifman S, Darvasi A: The value of isolated populations. Nat Genet. 2001, 28 (4): 309-310. 10.1038/91060.View ArticlePubMedGoogle Scholar
- The Genomatix software package [http://www.genomatix.de].
- Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005, 21 (2): 263-265. 10.1093/bioinformatics/bth457.View ArticlePubMedGoogle Scholar
- de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D: Efficiency and power in genetic association studies. Nat Genet. 2005, 37 (11): 1217-1223. 10.1038/ng1669.View ArticlePubMedGoogle Scholar
- Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001, 68 (4): 978-989. 10.1086/319501.PubMed CentralView ArticlePubMedGoogle Scholar
- Stephens M, Donnelly P: A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003, 73 (5): 1162-1169. 10.1086/379378.PubMed CentralView ArticlePubMedGoogle Scholar
- Li N, Stephens M: Modeling linkage disequilibrium and identifying recombination hotspots using single-nucleotide polymorphism data. Genetics. 2003, 165 (4): 2213-2233.PubMed CentralPubMedGoogle Scholar
- Crawford DC, Bhangale T, Li N, Hellenthal G, Rieder MJ, Nickerson DA, Stephens M: Evidence for substantial fine-scale variation in recombination rates across the human genome. Nat Genet. 2004, 36 (7): 700-706. 10.1038/ng1376.View ArticlePubMedGoogle Scholar
- Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP: Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996, 66 (6): 2621-2624.View ArticlePubMedGoogle Scholar
- Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M: Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998, 3 (6): 508-511. 10.1038/sj.mp.4000425.View ArticlePubMedGoogle Scholar
- Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E: Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol. 2000, 20 (1): 105-107. 10.1097/00004714-200002000-00021.View ArticlePubMedGoogle Scholar
- Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000, 23 (5): 587-590. 10.1016/S0893-133X(00)00132-9.View ArticlePubMedGoogle Scholar
- Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ: Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry. 2002, 7 (10): 1115-1119. 10.1038/sj.mp.4001141.View ArticlePubMedGoogle Scholar
- Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003, 301 (5631): 386-389. 10.1126/science.1083968.View ArticlePubMedGoogle Scholar
- Kaufman J, Yang BZ, Douglas-Palumberi H, Houshyar S, Lipschitz D, Krystal JH, Gelernter J: Social supports and serotonin transporter gene moderate depression in maltreated children. Proc Natl Acad Sci U S A. 2004, 101 (49): 17316-17321. 10.1073/pnas.0404376101.PubMed CentralView ArticlePubMedGoogle Scholar
- Feinn R, Nellissery M, Kranzler HR: Meta-analysis of the association of a functional serotonin transporter promoter polymorphism with alcohol dependence. Am J Med Genet B Neuropsychiatr Genet. 2005, 133 (1): 79-84.View ArticleGoogle Scholar
- Nickerson DA, Taylor SL, Weiss KM, Clark AG, Hutchinson RG, Stengard J, Salomaa V, Vartiainen E, Boerwinkle E, Sing CF: DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene. Nat Genet. 1998, 19 (3): 233-240. 10.1038/907.View ArticlePubMedGoogle Scholar
- Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, Dawson EP: Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics. 2004, 5 (7): 895-931. 10.1517/14622422.214.171.1245.View ArticlePubMedGoogle Scholar
- Badagnani I, Chan W, Castro RA, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE, Carlson EJ, Burchard EG, Giacomini KM: Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics J. 2005, 5 (3): 157-165. 10.1038/sj.tpj.6500303.View ArticlePubMedGoogle Scholar
- Nielsen R: Molecular signatures of natural selection. Annu Rev Genet. 2005, 39: 197-218. 10.1146/annurev.genet.39.073003.112420.View ArticlePubMedGoogle Scholar
- Cheong HS, Lee SO, Choi CB, Sung YK, Shin HD, Bae SC: MERTK polymorphisms associated with risk of haematological disorders among Korean SLE patients. Rheumatology (Oxford). 2007, 46 (2): 209-214. 10.1093/rheumatology/kel182.View ArticleGoogle Scholar
- Makikyro TH, Hakko HH, Timonen MJ, Lappalainen JA, Ilomaki RS, Marttunen MJ, Laksy K, Rasanen PK: Smoking and suicidality among adolescent psychiatric patients. J Adolesc Health. 2004, 34 (3): 250-253.View ArticlePubMedGoogle Scholar
- Yang BZ, Zhao H, Kranzler HR, Gelernter J: Practical population group assignment with selected informative markers: characteristics and properties of Bayesian clustering via STRUCTURE. Genet Epidemiol. 2005, 28 (4): 302-312. 10.1002/gepi.20070.View ArticlePubMedGoogle Scholar
- The National Center for Biotechnology Information (NCBI) [http://www.ncbi.nlm.nih.gov/].
- The PRIMER3 software [http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi].
- The NCBI dbSNP [http://www.ncbi.nlm.gov/SNP].
- Web application SLIDER [http://genapps.uchicago.edu/index.html].
- Bamshad M, Wooding SP: Signatures of natural selection in the human genome. Nat Rev Genet. 2003, 4 (2): 99-111. 10.1038/nrg999.View ArticlePubMedGoogle Scholar
- The POWERMARKER software [http://www.powermarker.net].
- Jurka J, Kapitonov VV, Pavlicek A, Klonowski P, Kohany O, Walichiewicz J: Repbase Update, a database of eukaryotic repetitive elements. Cytogenet Genome Res. 2005, 110 (1-4): 462-467. 10.1159/000084979.View ArticlePubMedGoogle Scholar
- Web application CENSOR [http://www.girinst.org].
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.